The Schug Laboratory
Alterations in the acquisition and metabolism of nutrients are now firmly recognized as hallmarks of cancer development. Many, if not all, oncogenes and tumor suppressor genes induce metabolic reprogramming in cancer cells through changes in the regulation of enzymes and transporters. These changes are necessary for cancer cells to meet the combined biomass and energy demands for growth and are only satisfied by increased capture and synthesis of cellular building blocks such as sugars, fats, and proteins. However, cancer cells often invade other tissues where the availability of certain nutrients is drastically different or grow so quickly that the blood supply, and the accessibility to oxygen and other nutrients that comes with it, becomes scarce. During these conditions of nutrient stress, many cancer cells will adapt and use other resources to survive.
The Schug laboratory is interested in identifying and therapeutically targeting the metabolic changes that arise during the development of cancer as well as in response to drug resistance. They combine cell biology, biochemistry, metabolomics, and genomics to uncover novel metabolic vulnerabilities in cancer. These targets are then fed into an active drug discovery program to develop effective therapeutic strategies for the improved treatment of cancer patients.
Jessica Casciano, Ph.D.
Katelyn Miller, Ph.D.